Chimeric antigen receptor T cells and management of toxicities: Implications of biomarkers Book Section
| Authors: | Wudhikarn, K.; Alarcón Tomas, A.; Murata, K.; Perales, M. A. |
| Editors: | Ramanathan, L. V.; Fleisher, M.; Duffy, M. J. |
| Article/Chapter Title: | Chimeric antigen receptor T cells and management of toxicities: Implications of biomarkers |
| Abstract: | Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment armamentarium of relapsed/refractory hematologic malignancies, enabling high response rates, and potential cure. Despite these impressive antitumor effects, many patients experience relapse or fail to respond after receiving CAR T cells. There are also several unique side effects associated with morbidity and mortality, including immune-mediated phenomena, prolonged cytopenias, B-cell aplasia, and hypogammaglobulinemia. Several studies have explored predictive biomarkers to identify patients at risk of treatment failure or adverse events. A biomarker-based approach to CAR T-cell treatment may improve patient selection by identifying risk factors for nonresponders and for severe toxicities, as well as help researchers identify targets for novel CAR T-cell products. © 2022 Elsevier Inc. All rights reserved. |
| Keywords: | biomarkers; hematologic malignancy; car t cell; chimeric antigen receptor t cell |
| Book Title: | Cancer Biomarkers: Clinical Aspects and Laboratory Determination |
| ISBN: | 978-0-12-824302-2 |
| Publisher: | Elsevier Inc. |
| Publication Place: | Amsterdam, Netherlands |
| Date Published: | 2022-01-01 |
| Start Page: | 245 |
| End Page: | 281 |
| Language: | English |
| DOI: | 10.1016/b978-0-12-824302-2.00012-6 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 8; This is the 5th volume in Clinical Aspects and Laboratory Determination -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
33Murata -
913Perales -
312Fleisher -
77Ramanathan -
15Wudhikarn
Related MSK Work